Istituto Nazionale per lo Studio e la Cura dei Tumori Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Forli Italy (2007)

Organization Overview

First Clinical Trial
2007
NCT01031030
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Fondazione IRCCS "Istituto Nazionale Tumori" - Milan (Italy) | IRST IRCCS | IRST IRCCS, Meldola | IRST IRCCS, Meldola-Cesena | IRST IRCCS, Meldola (FC) | IRST - ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI | Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST Italy | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST IRCCS , Meldola Italy | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) Meldola | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Via Maroncelli 40, 47014 Meldola, ITALY | UO Immunoterapia e Laboratorio TCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l IRCCS | UO Immunoterapia e Laboratorio TCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l IRCCS

Active Ingredients

Drugs in Phase 4 Trials (1)

vinorelbine (navelbine) (4 trials)

Drugs in Phase 3 Trials (20)

abemaciclib (verzenio) (1 trial)

bevacizumab (avastin) (2 trials)

capecitabine (xeloda) (4 trials)

cetuximab (erbitux) (1 trial)

cisplatin (platinol) (3 trials)

cyclophosphamide (cytoxan) (3 trials)

dexamethasone (1 trial)

docetaxel (taxotere) (4 trials)

epirubicin (ellence) (2 trials)

fluorouracil (efudex) (8 trials)

gemcitabine (gemzar) (5 trials)

imatinib (gleevec) (1 trial)

irinotecan (Camptosar) (4 trials)

leucovorin (5 trials)

naltrexone (revia) (1 trial)

netupitant (Akynzeo) (1 trial)

oxaliplatin (eloxatin) (4 trials)

palbociclib (ibrance) (1 trial)

palonosetron (aloxi) (1 trial)

ribociclib (kisqali) (1 trial)

Drugs in Phase 2 Trials (36)

177lu-dotatoc (1 trial)

aldesleukin (Proleukin) (4 trials)

autologous dc-vaccines (2 trials)

autologous dendritic cells loaded with autologous tumor lysate (1 trial)

ctt1057 (1 trial)

dehydroepiandrosterone (1 trial)

dotatoc-90y (1 trial)

doxorubicin (Doxil) (3 trials)

doxycycline (vibramycin) (1 trial)

durvalumab (imfinzi) (1 trial)

everolimus (zortress) (1 trial)

f16sip (1 trial)

fotemustine (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

inotuzumab ozogamicin (besponsa) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

lanreotide (somatuline depot) (1 trial)

levoleucovorin (fusilev) (1 trial)

losartan (cozaar) (1 trial)

lutetium (177Lu) vipivotide tetraxetan (Pluvicto) (3 trials)

lutetium dotatate lu-177 (Lutathera) (2 trials)

octreotide (sandostatin) (1 trial)

olaparib (lynparza) (2 trials)

paclitaxel (taxol) (2 trials)

pembrolizumab (keytruda) (2 trials)

pemetrexed (alimta) (2 trials)

prednisone (meticorten) (1 trial)

radium-223 (xofigo) (1 trial)

sargramostim (leukine) (1 trial)

sitagliptin (januvia) (2 trials)

somatostatin (1 trial)

temozolomide (temodar) (3 trials)

trastuzumab (herceptin) (1 trial)

tumor-pulsed dendritic cells (2 trials)

vemurafenib (zelboraf) (1 trial)

venetoclax (venclexta) (1 trial)

Drugs in Phase 1 Trials (3)

autologous dendritic cells (1 trial)

bortezomib (velcade) (1 trial)

lapatinib (tykerb) (1 trial)

Drugs in Other Trials (1)

Ga 68 PSMA-11 (Illuccix) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Adenoma, Islet Cell (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 4)

Carcinoma, Renal Cell (Phase 2)

Colorectal Neoplasms (Phase 3)

Coronavirus Infections (Phase 2)

Disease Progression (Phase 1)

Esophageal Neoplasms (Phase 3)

Gastrointestinal Stromal Tumors (Phase 3)

Glioblastoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Melanoma (Phase 2)

Mesothelioma (Phase 1)

Nausea (Phase 3)

Neoplasms (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Neuroendocrine Tumors (Phase 2)

Pancreatic Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Sarcoma (Phase 2)

Skin Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 54
  • # of Trial APIs: 61